Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of FF/UMEC/VI (Trelegy) in Indian Patients with COPD
NCT04923347Phase 4Completed
- Sponsor
- GSK
- Start
- Jun 2023
- Primary completion
- Mar 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of fluticasone furoate + umeclidinium bromide + vilanterol trifenatate in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Jun 2023; status: completed.
02
Drugs
fluticasone furoate + umeclidinium bromide + vilanterol trifenatate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04923347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04923347.